[go: up one dir, main page]

KR920019342A - 골질환 치료제 - Google Patents

골질환 치료제 Download PDF

Info

Publication number
KR920019342A
KR920019342A KR1019920005743A KR920005743A KR920019342A KR 920019342 A KR920019342 A KR 920019342A KR 1019920005743 A KR1019920005743 A KR 1019920005743A KR 920005743 A KR920005743 A KR 920005743A KR 920019342 A KR920019342 A KR 920019342A
Authority
KR
South Korea
Prior art keywords
disease treatment
bone disease
bone
droroxifene
approved
Prior art date
Application number
KR1019920005743A
Other languages
English (en)
Other versions
KR100196810B1 (ko
Inventor
카즈아키 니이쿠라
요시미츠 나카지마
요시타다 노츠
류지 오노
오사무 나카야마
Original Assignee
원본미기재
클링게 파르마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 클링게 파르마 게엠베하 filed Critical 원본미기재
Publication of KR920019342A publication Critical patent/KR920019342A/ko
Application granted granted Critical
Publication of KR100196810B1 publication Critical patent/KR100196810B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

골질환 치료제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (1)

  1. 약제로 승인된 드롤록시펜 또는 그것의 염을 활성성분으로 포함하는 골질환 치료제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920005743A 1991-04-09 1992-04-07 골질환치료제 KR100196810B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3166944A JPH04312526A (ja) 1991-04-09 1991-04-09 骨疾患治療剤
JP91-166944 1991-04-09

Publications (2)

Publication Number Publication Date
KR920019342A true KR920019342A (ko) 1992-11-19
KR100196810B1 KR100196810B1 (ko) 1999-06-15

Family

ID=15840531

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920005743A KR100196810B1 (ko) 1991-04-09 1992-04-07 골질환치료제

Country Status (14)

Country Link
US (1) US5254594A (ko)
EP (1) EP0509317B1 (ko)
JP (1) JPH04312526A (ko)
KR (1) KR100196810B1 (ko)
AT (1) ATE114113T1 (ko)
AU (1) AU648154B2 (ko)
CA (1) CA2065093C (ko)
DE (1) DE69200675T2 (ko)
DK (1) DK0509317T3 (ko)
EE (1) EE02971B1 (ko)
ES (1) ES2064130T3 (ko)
HK (1) HK1004257A1 (ko)
IE (1) IE66900B1 (ko)
ZA (1) ZA922527B (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
ATE177008T1 (de) * 1992-10-27 1999-03-15 Nippon Kayaku Kk Verwendung von toremifene für die behandlung von sle
US5886049A (en) * 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
EP0635264B1 (en) * 1993-06-24 1997-09-10 Eli Lilly And Company Antiestrogenic 2-phenyl-3-aroylbenzothiophenes as hypoglycemic agents
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
ZA956029B (en) 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
US5489587A (en) * 1995-01-20 1996-02-06 Eli Lilly And Company Benzofurans used to inhibit bone loss
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
CA2207141A1 (en) * 1996-07-15 1998-01-15 David Thompson Berg Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP0897720A1 (en) * 1997-08-13 1999-02-24 Pfizer Products Inc. Droloxifene for prevention of breast cancer
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
ATE506986T1 (de) * 1999-08-13 2011-05-15 Curadis Gmbh Substanzen und mittel zur positiven beeinflussung von kollagen
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
LT3354276T (lt) 2007-11-13 2020-04-27 Meritage Pharma, Inc. Kompozicijos, skirtos skrandžio ir žarnyno uždegimo gydymui
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency

Also Published As

Publication number Publication date
HK1004257A1 (en) 1998-11-20
ATE114113T1 (de) 1994-12-15
EP0509317A3 (en) 1993-03-03
EE02971B1 (et) 1997-04-15
ES2064130T3 (es) 1995-01-16
AU1399492A (en) 1992-10-15
EP0509317B1 (en) 1994-11-17
IE66900B1 (en) 1996-02-07
ZA922527B (en) 1992-12-30
EP0509317A2 (en) 1992-10-21
DE69200675D1 (de) 1994-12-22
JPH04312526A (ja) 1992-11-04
AU648154B2 (en) 1994-04-14
US5254594A (en) 1993-10-19
KR100196810B1 (ko) 1999-06-15
IE921116A1 (en) 1992-10-21
DK0509317T3 (da) 1995-01-30
DE69200675T2 (de) 1995-03-16
CA2065093C (en) 1995-10-03
CA2065093A1 (en) 1992-10-10

Similar Documents

Publication Publication Date Title
KR920019342A (ko) 골질환 치료제
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
KR890015742A (ko) 이병치료용 국소 제제
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
PT998287E (pt) Utilizacao de levobupivacaina
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
KR920016088A (ko) 하부 요로 질환의 치료
KR940018087A (ko) 진통제 및 소염제로서의 6-클로로-5-플루오로-3-(2-테노일)-2-옥신돌-ⅰ-카복스아미드
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
NO985571L (no) Legemiddel for autoimmunsykdommer
KR930019224A (ko) 유산 위험 치료제
KR890001540A (ko) 심부전증 치료제
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
KR900012622A (ko) 피부질환치료 조성물
DE69012742D1 (de) Azolderivate und fungizide Medikamente, diese als wirkende Komponente enthaltend.
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR900017599A (ko) 종양 치료용 약학 조성물
KR930702016A (ko) 골다공증 치료제
FR2677223B1 (fr) Composition insecticide a base de rotenone, notamment pour le traitement des parasites humains et animaux.
KR880009644A (ko) 궤양성 대장질환 치료용 약한 조성물
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
KR890000089A (ko) 신장 질환 치료제
KR890001543A (ko) 당뇨병 치료제
KR950007852A (ko) 우라실을 유효성분으로 함유하는 관절염 치료제

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920407

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970325

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920407

Comment text: Patent Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981127

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20021105